Biblio
“Increase of α-Secretase ADAM10 in Platelets Along Cognitively Healthy Aging.”, J Alzheimers Dis, vol. 50, no. 3, pp. 817-26, 2016.
, “Different Expression Patterns of Amyloid-β Protein Precursor Secretases in Human and Mouse Hippocampal Neurons: A Potential Contribution to Species Differences in Neuronal Susceptibility to Amyloid-β Pathogenesis.”, J Alzheimers Dis, vol. 51, no. 1, pp. 179-95, 2016.
, “microRNA 221 Targets ADAM10 mRNA and is Downregulated in Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 1, pp. 113-123, 2018.
, “The Evolution of Caregiver Burden in Frontotemporal Dementia with and without Amyotrophic Lateral Sclerosis.”, J Alzheimers Dis, vol. 49, no. 3, pp. 875-85, 2016.
, “Examining the Relationship Between Autobiographical Memory Impairment and Carer Burden in Dementia Syndromes.”, J Alzheimers Dis, vol. 51, no. 1, pp. 237-48, 2016.
, “"I Don't Think Of It As An Illness": Illness Representations in Mild to Moderate Dementia.”, J Alzheimers Dis, vol. 51, no. 1, pp. 139-50, 2016.
, “High Caregiver Burden in Young Onset Dementia: What Factors Need Attention?”, J Alzheimers Dis, vol. 61, no. 2, pp. 537-543, 2018.
, “Needs of Dementia Family Caregivers in Spain During the COVID-19 Pandemic.”, J Alzheimers Dis, vol. 80, no. 2, pp. 533-537, 2021.
, “The Impact of a Global Pandemic on People Living with Dementia and Their Care Partners: Analysis of 417 Lived Experience Reports.”, J Alzheimers Dis, vol. 80, no. 2, pp. 865-875, 2021.
, “A Comparison of Well-Being of Carers of People with Dementia and Their Ability to Manage Before and During the COVID-19 Pandemic: Findings from the IDEAL Study.”, J Alzheimers Dis, vol. 88, no. 2, pp. 679-692, 2022.
, “Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease.”, Cell, vol. 153, no. 3, pp. 707-20, 2013.
, “Genetic Influences on Plasma Homocysteine Levels in African Americans and Yoruba Nigerians.”, J Alzheimers Dis, vol. 49, no. 4, pp. 991-1003, 2016.
, “Region-Specific Vulnerability to Oxidative Stress, Neuroinflammation, and Tau Hyperphosphorylation in Experimental Diabetes Mellitus Mice.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1209-24, 2016.
, “Bridging Integrator 1 (BIN1) Genotypes Mediate Alzheimer's Disease Risk by Altering Neuronal Degeneration.”, J Alzheimers Dis, vol. 52, no. 1, pp. 179-90, 2016.
, “Increased Electron Paramagnetic Resonance Signal Correlates with Mitochondrial Dysfunction and Oxidative Stress in an Alzheimer's disease Mouse Brain.”, J Alzheimers Dis, vol. 51, no. 2, pp. 571-80, 2016.
, “A Mitochondrial Role of SV2a Protein in Aging and Alzheimer's Disease: Studies with Levetiracetam.”, J Alzheimers Dis, vol. 50, no. 1, pp. 201-15, 2016.
, “STX, a Novel Membrane Estrogen Receptor Ligand, Protects Against Amyloid-β Toxicity.”, J Alzheimers Dis, vol. 51, no. 2, pp. 391-403, 2016.
, “Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 3, pp. 873-86, 2016.
, “Triceps and Subscapular Skinfold in Men Aged 40-65 and Dementia Prevalence 36 Years Later.”, J Alzheimers Dis, vol. 57, no. 3, pp. 873-883, 2017.
, “Two Phase 2 Multiple Ascending-Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1131-43, 2016.
, “Intranasal TAT-haFGF Improves Cognition and Amyloid-β Pathology in an AβPP/PS1 Mouse Model of Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 4, pp. 985-90, 2016.
, “Synthetic Fragment of Receptor for Advanced Glycation End Products Prevents Memory Loss and Protects Brain Neurons in Olfactory Bulbectomized Mice.”, J Alzheimers Dis, vol. 61, no. 3, pp. 1061-1076, 2018.
, “The Oral Iron Chelator, Deferasirox, Reverses the Age-Dependent Alterations in Iron and Amyloid-β Homeostasis in Rat Brain: Implications in the Therapy of Alzheimer's Disease.”, J Alzheimers Dis, vol. 49, no. 3, pp. 681-93, 2016.
, “AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics.”, J Alzheimers Dis, vol. 50, no. 4, pp. 1109-23, 2016.
, “Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years.”, J Neuropathol Exp Neurol, vol. 70, no. 11, pp. 960-9, 2011.
,